Oral Drug Delivery Utilizing Mesoporous Compositions

University of Texas at Dallas
posted on 09/14/2009

• request more info 
•   
•  LICENSE ONLINE

Invention:

This technology facilitates the oral delivery of water-insoluble drugs using novel mesoporous compositions comprising vitamin E and alumina. The synthesis conditions can be modified to control particle morphology, while maintaining a hexagonal mesoporous structure.

For the primary application, this technology allows for a lipid-soluble drug to be encapsulated inside a micelle in which the molecules are oriented such that the hydrophilic end is exposed to water and the core is hydrophobic. The micelles are then coated with molecular sieve material. The result is a porous ceramic powder, which contains vitamin E, which contains the lipid-soluble drug. This enables a pill that once it enters the stomach, the ceramic coating would dissolve away, releasing the micelles which would then go to the intestines to release lipid-soluble drugs.

Other potential applications include uses as a catalyst by fixation of large active complexes in the mesopores; as fiber optic sensors by depositing the mesoporous composition comprising a fluorescent dye at the tip of an optical fiber; and in the preparation of mesoporous membranes for use in separation, fuel cells, and catalytic membrane reactors.

Background:

Drug insolubility is one of the most challenging issues in the development of many pharmaceutical products. Over one third of the drugs listed in the U.S. Pharmacopedia and about half of new chemical entities are insoluble or poorly soluble in water. As a result, many drugs are marketed as sub-optimal formulations, often giving poor or erratic bioavailability or a greater risk of adverse side effects. This technology can be used to facilitate the in situ delivery of insoluble or poorly soluble drugs.

Benefits:

·         Can deliver water-insoluble drugs orally

·         Can mask the flavor of orally-delivered drugs/ nutraceuticals

·         Can be synthesized under specific conditions to produce varied morphologies

·         Potentially can be used to deliver insulin orally

IP Status:

·         US utility patent issued

·         Divisional patent pendingSssssss7

Inventors:

• Kenneth Balkus, Professor of Chemistry,The University of Texas at Dallas

• Ying Ma, Postdoctoral Student in Chemistry, The University of Texas at Dallas

Contact: Brent Schultze, email: brent.schultze@utdallas.edu, phone: 972-883-4589

Tech ID: 01-007